Novel Intraocular Therapy in Non-infectious Uveitis of the Posterior Segment of the Eye by Mikhail, Michael & Sallam, Ahmed
 
 





Medical Hypothesis, Discovery &Innovation  
Ophthalmology Journal 
   
 
 
Novel Intraocular Therapy in Non-infectious Uveitis of the 
Posterior Segment of the Eye 
 
Michael Mikhail FRCS (Glasg), MRCOphth¹, Ahmed Sallam PhD, FRCS (Glasg), FRCOphth² 
 
¹Royal Victoria Hospital, Belfast, UK, ² Gloucestershire Hospitals NHS Foundation Trust, UK 
 
ABSTRACT 
This article reviews the new clinically relevant data regarding the intraocular treatment of non-infectious 
uveitis. Triamcinolone acetonide is the most commonly used intravitreal corticosteroid for treatment of 
uveitis and uveitic macular oedema. The drug is available at low cost but it is associated with a high risk of 
raised intraocular pressure (IOP) and cataract and is not licensed for intraocular use. Dexamethasone 
implant (Ozurdex®) appears to have a better safety profile, and a slightly long-lasting effect than 
triamcinolone acetonide. Fluocinolone acetonide implant (Retisert®) implant allows the release of 
corticosteroids at a constant rate over a 3-year period, but it requires surgical placement and its use is 
associated with a very high risk of cataracts and raised intraocular pressure. Iluvien® is another 
fluocinolone acetonide implant that could represent a more convenient treatment option for such cases in 
the future as it can be inserted into the vitreous cavity through 25-gauge injector system in an outpatient 
setting. To circumvent the risks associated with corticosteroids use, non-corticosteroids related 
therapeutics including intravitreal methotrexate; anti-vascular endothelial growth factor treatments and 
intravitreal sirolimus have been recently developed. 
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INTRODUCTION 
Uveitis belongs to a group of intraocular inflammatory 
disorders affecting the uvea, which can cause significant 
visual impairment and may result in partial or complete 
loss of vision. It encompasses a wide range of clinical 
phenotypes, and can be classified anatomically into 
anterior, intermediate, posterior and panuveitis (1). 
  Uveitis can also be divided based on its aetiology into 
infectious, non-infectious, and masquerade syndromes 
(neoplastic and drug-induced). The course of uveitis may 
be defined as acute, recurrent or chronic (1). It is 
estimated that non-infectious uveitis involving the 
posterior segment of the eye affects around 3 to 10 
persons per 100,000 in the European Union (1,500 and 
5,000 cases per year in England). The true incidence is 
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difficult to determine as some cases may resolve 
spontaneously and not present clinically (1,2). 
  Uveitis affecting the posterior segment of the eye is 
often unresponsive to topical administration of steroids 
due to less than optimum therapeutic drug penetration 
beyond the lens. Periocular and subtenon steroids could 
be effective in treating some patients with uveitis 
associated cystoid macular edema (CME) but their 
successful use has been limited to mild cases due to poor 
absorption of the drug when delivered through this route 
intraocularly (3). Long-term systemic corticosteroid 
therapy is required in patients with an associated 
systemic disease and in those with bilateral ocular 
inflammation. Although effective, it is associated with a 
variety of potentially serious adverse effects such as 
induction or worsening of hypertension and diabetes 
mellitus, osteoporosis, and adrenal suppression. Second 
line immunosuppressive drugs and biological agents such 
as tumour necrosis factor alpha inhibitors are used as 
‘steroid sparing’ treatments, however, they have their 
own systemic risks, which are likely to limit their clinical 
use. 
  Intravitreal drug delivery allows rapid and high 
concentrations of the drug into the eye as it bypasses the 
blood ocular barriers and at the same time is associated 
with the lowest incidence of drug related systemic 
toxicity (3). However, its significant drawbacks include 
the possibility of retinal toxicity and mechanical injury to 
intraocular structures like the crystalline lens or retina. 
Intraocular injections are also associated with a small risk 
of endophthalmitis.  
  This article reviews the current literature on the use of 
intraocular drugs for treatment of non-infectious uveitis 
affecting the posterior segment of the eye. 
Triamcinolone acetonide is currently the most commonly 
used intravitreal treatment. However, despite its 
potency, it has a short therapeutic duration as well as a 
significant adverse effect profile in terms of cataract 
formation and increase in IOP. Recently, several slow 
release corticosteroid implants have been developed in 
order to prolong the effectiveness of the drug. New non-
corticosteroid related therapeutics; including intravitreal 
methotrexate, anti-vascular endothelial growth factor 
treatment and intravitreal sirolimus to treat intraocular 
treatment of non-infectious uveitis have also been 
developed to avoid the ocular side effects inherent to the 
use of intraocular steroids. 
 
Intravitreal triamcinolone acetonide 
The use of intravitreal triamcinolone acetonide (IVTA) at 
a concentration of 2-4mg in 0.1ml is currently a common 
practice for the treatment of uveitis affecting the 
posterior segment of the eye (4-6). The Federal Drugs 
Administration (FDA) in the USA has approved two 
formulations of triamcinolone acetonide for intraocular 
use. Triamcinolone acetonide is not licensed for 
intraocular use in the European Union but is routinely 
employed for the treatment of non-infectious posterior 
uveitis and uveitic CME. The typical duration of the 
treatment is 4-5 months, with the maximum effect on 
vision occurring within six weeks (4). A study of the 
pharmacokinetics of the drug following an injection of 
0.1 ml (0.3mg) of triamcinolone acetonide in 42 
vitrectomised eyes and 42 non-vitrectomised eyes 
showed that IVTA decreases more rapidly in the 
vitrectomised eye than in the non-vitrectomised eye (5). 
Kok et al., (6) studied the short-term outcome of 
intravitreal triamcinolone acetate in the treatment of 
uveitic CME. This study is the largest of its kind and 
involved 65 eyes of 54 patients. All had uveitis related 
CME which was unresponsive to treatment combinations 
of oral corticosteroid, periocular orbital floor 
corticosteroid injections, and second-line 
immunosuppressive agents. Over a mean follow-up of 8 
months, 83% of eyes responded to a 4mg dose of IVTA of 
which 51% gained at least two Snellen lines. The 
improvement in VA was more significant if the duration 
of CME before IVTA was 12 months and if patients were 
60 years old. This treatment protocol also enabled the 
doses of oral corticosteroids and second line  
immunosuppressive agents to be reduced (6). 
  As mentioned before, the side effects of steroids 
significantly limit their use. The most common adverse 
side effects are raised IOP and cataract. Raised 
intraocular pressure is seen in 29%-50% of patients 
within a year (7). In most cases, this is transient and can 
be controlled medically, but there have been a few 
reports of patients requiring surgical intervention (8). 
Previous studies reported the rate of cataract 
development at 15-30% after one injection (9). 
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Dexamethasone (Ozurdex®) intravitreal implant 
Ozurdex® (Allergan Pharmaceuticals) is a biodegradable 
dexamethasone intravitreal implant that contains 0.7mg 
of dexamethasone. Ozurdex® is placed intravitreally 
through the pars plana with an injector using a 22-gauge 
needle device. The insert provides peak doses for an 
initial 2 months followed by lower doses for up to 6 
months and can be safely performed as an outpatient 
procedure. Ozurdex® received FDA approval in June 2009 
for the treatment of macular edema associated with 
retinal vein occlusion, and for the treatment of non-
infectious posterior uveitis in September 2010. 
  The clinical efficacy of Ozurdex® in the treatment of 
non-infectious posterior uveitis has been assessed in a 
single study; a phase III, multicentre, randomised, 
double-masked, sham-controlled trial known as the 
HURON study (chronic uveitis evaluation of the 
intravitreal dexamethasone implant) (10). The 26-week, 
prospective, multicenter, masked study included 229 
patients with intermediate or posterior uveitis. 
Participants were randomized to receive a single 
treatment with a 0.7-mg dexamethasone implant (n=77), 
a 0.35-mg dexamethasone implant (n=76), or a sham 
procedure (n=76). Eighty-one percent of patients had 
intermediate uveitis. At the eighth week primary 
endpoint, 47%, 36% and 12% of patients had no vitreous 
inflammation, respectively. The response was maintained 
at week 26. In addition, both treatment groups achieved 
a 3-line improvement in visual acuity and reduced central 
macular thicknesses on optical coherence tomography 
(OCT) at 8 weeks that was statistically significant 
compared to the sham group. Regarding the 
complication rate, the incidence of cataract reported in 
phakic eyes was nine of 62 (15%) in the 0.7-mg implant 
group. Twenty-three percent of eyes in the 0.7 mg 
Ozurdex® group required IOP-lowering agents but none 
needed surgical intervention for glaucoma. The effect of 
repeat injections on cataract and IOP remains unknown. 
 
Fluocinolone acetonide (Retisert®) implant 
The Retisert® intravitreal implant (Bausch & Lomb, 
Rochester, New York, USA) is a slow release 
corticosteroid implant that contains fluocinolone 
acetonide and releases the drug at a constant rate over a 
three year period of time. In chronic uveitis, cumulative 
structural damage and loss of vision result from 
recurrent episodes of inflammation (11). The goal of 
uveitis treatment should not only be to suppress 
inflammation when it occurs but also to attain complete 
remission of inflammation in the longer term. 
Fluocinolone is a corticosteroid with a high potency, low 
solubility and a very short duration of action in the 
systemic circulation (12). Implantation of this device 
requires surgery with the implant being placed through a 
pars plana incision and anchored to the sclera with 
sutures (13,14). 
  The efficacy of fluocinolone implant has been evaluated 
in several studies (15-17). In one of these studies, a total 
of 278 patients with recurrent non-infectious posterior 
uveitis were randomized to receive a 0.59-mg (n = 110) 
or 2.1-mg (n = 168) implant. Results showed that the 
Retisert® reduced the rate of recurrences from 51.4% in 
the 34 weeks preceding implantation to 6.1% post-
implantation in the study eyes. Comparatively, there was 
a significant increase in the recurrence rate in the fellow 
non-implanted eyes from 20.3% pre-implantation to 
42.0% post-implantation. Visual acuity was stabilized or 
improved in 87% of implanted eyes. The percentage of 
eyes that required systemic medications, periocular 
injections, and topical corticosteroids decreased from 
52.9%, 63.0%, and 35.7%, pre-implantation to 12.1%, 
2.2%, and 16.5% post-implantation, respectively. 
  In terms of complications, cataract surgery was required 
in 93% of the cases and 51.1% of the eyes receiving the 
implant required antihypertensive drops, with 5.8% 
undergoing glaucoma filtering procedures (16). Other 
reported side effects include hypotony (18), implant 
malfunction (19), retinal detachment, endophthalmitis, 
scleral thinning (18), and the development of 
opportunistic intraocular infections including herpetic 
retinitis (20-21). 
  Further evidence to support the use of fluocinolone 
acetonide implant in vision threatening non infectious 
uveitis stems from The Multicenter Uveitis Steroid 
Treatment (MUST) trial (22), a randomized controlled 
clinical trial comparing local therapy with fluocinolone 
acetonide intraocular implant standard therapy with 
systemic corticosteroid therapy supplemented, when 
indicated, by corticosteroid-sparing therapies. Study 
results (23) indicated that in each treatment group, mean 
visual acuity improved over 24 months, with neither 
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approach being demonstrably superior to the other. 
Therefore, the specific advantages and disadvantages 
associated with each treatment should dictate which of 
the two treatments should be selected, which would 
likely be a consideration of individual patients' particular 
circumstances. 
 
Fluocinolone acetonide (Iluvien®) implant 
Iluvien® (Alimera Sciences Inc.) is another fluocinolone 
acetonide intravitreal insert, which is designed to deliver 
corticosteroid to the retina for up to 3 years (24).  It is 
injected through a 25-gauge injector system in an 
outpatient setting. Although, it uses same drug matrix as 
Retisert®, it releases the drug at a lower dose (0.2 or 
0.5ug/day versus 0.59ug/day with Retisert®) (23). There 
is no published evidence for its effect in treating uveitis; 
however, positive effect on diabetic macular oedema 
was shown on a large scale previous study (25). 
 
Antivascular endothelial growth factor agents 
The pathophysiology of CME associated with uveitis is 
not completely understood. Chronic intraocular 
inflammation is associated with increased production of 
inflammatory mediators, including vascular endothelial 
growth factor (VEGF), which are hypothesized to disrupt 
the blood-retinal barrier on the endothelium of retinal 
vessels, resulting in subsequent macular edema. A study 
in human eyes with uveitis and CME showed increased 
concentration of VEGF in the aqueous humor (26). It is 
suspected to play a role in the loss of vascular integrity in 
the eye and is known to be induced by inflammatory 
cytokines, such as interleukin 1 and interleukin 6, which 
have been found to be elevated intraocularly in uveitis 
patients (27,28). Therefore, inhibition of inappropriate 
VEGF activity is a potential new approach to treatment of 
CME in this population.  
  A prospective, non-comparative, interventional case 
series (29) looking at seven consecutive patients with 
controlled uveitis and refractory CME who had little to 
no results from corticosteroid treatment were studied by 
Nisha and associates. At 3 months, the mean increase in 
visual acuity for the 6 patients who completed follow-up 
was 13 letters (2.5 lines). Both VA and central retinal 
thickness improved significantly between baseline and 3 
months demonstrating that intravitreal ranibizumab 
could result in regression of uveitis-associated CME in 
patients who are refractory to or intolerant of systemic 
corticosteroid therapy.  
  Several studies (30-32) have also compared the use of 
intravitreal bevacizumab to IVTA in the treatment of 
uveitic macular oedema. They all concluded that there 
were better visual improvement and decreased macular 
thickness in the IVTA treated eyes.  
  Anti-VEGF agents have the advantage over various 
corticosteroids since they are much less likely to cause 
cataract progression or a rise in IOP. However, they have 
less of an anti-inflammatory effect, making them less 
suitable for the treatment of severe CME that is primarily 
driven by inflammation (33).  Nevertheless, anti-VEGF 
agents do have a pivotal role in the treatment of 
inflammatory choroidal neovascular membranes (CNV). 
Adan et al., (34) assessed the effects of intravitreal 
bevacizumab injection as primary treatment of 
inflammatory CNV. The study demonstrated complete 
resolution of CNV in 100% of eyes. Of a total of nine eyes 
that were followed for seven months, visual 
improvement occurred in eight eyes and stabilized in one 
eye. No patient had visual deterioration and a mean 1.3 
injections/eye were needed. Chan et al., (35) reported 
visual and anatomic improvements in eyes with 
idiopathic CNV and CNV attributable to punctate inner 
choroidopathy (PIC) and central serous choroidopathy. 
All 15 eyes had improvement in VA with a mean 
improvement of 2.9 lines at six months, as well as a 
reduction in central foveal thickness on OCT. Further 
studies are warranted to define its exact role as a 
monotherapy for eyes with uveitic complications and the 
potential for combination treatment with corticosteroids. 
Finally, it is important to mention that use of anti-VEGF 
agents could be associated with risk of cardiovascular 
events, though this is debatable (36). 
 
Intravitreal Sirolimus 
Sirolimus is a macrolide antibiotic also known as 
rapamycin. It has broad immunosuppressive and anti-
proliferative properties (37-39).  Sirolimus arrests cell 
cycle progression by direct interaction with 
aimmunophilin FK binding protein 12 (FKBP-12) resulting 
in sirolimus-FKBP-12 complex which then binds to and 
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inhibits mammalian target of rapamycin (mTOR). The 
inhibition of mTOR blocks IL-2 mediated signal 
transduction pathways that prevent cell cycle 
progression (37-39). 
  Sirolimus as a Therapeutic Approach for Uveitis (SAVE) 
(40) is a prospective, randomized, open-label, phase I 
study that evaluated the ocular tolerability and efficacy 
of Sirolimus administered as subconjunctival or 
intravitreal injections in patients with non-infectious 
uveitis. Thirty patients were enrolled and randomized in 
1:1 ratio to receive either intravitreal or subconjunctival 
sirolimus injections at days 0, 60, and 120. Primary 
endpoint was at month 6 and all subjects with active 
uveitis at baseline showed reduction in vitreous haze. 
Changes in the inflammatory indices were statistically 
significant (p < 0.05) in both study groups. Thirty percent 
of patients gained one or more lines of visual acuity, 20% 
lost one or more lines, and 50% maintained the same 
visual acuity. No serious adverse events related to the 
study drug were demonstrated in this study.  
  Intravitreal sirolimus is currently being evaluated in a 
phase III study named SAKURA, which will assess the 
safety and efficacy of 3 different doses of this drug in 
non-infectious uveitis affecting the posterior segment of 
the eye. This study involves multiple centers from 
Europe, India, North America as well as the Middle East 
and has just finished recruiting. 
 
Anti-Tumor necrosis factor alpha 
Tumor necrosis factor alpha (TNF-α) is a pro-
inflammatory cytokine produced by macrophages and T-
cells. It plays an important role both in inflammation and 
apoptosis. In the eye, TNF-α appears to have a role in the 
pathogenesis of inflammatory, edematous, neovascular 
and neurodegenerative disorders (41-43). 
Drugs that neutralize TNF-α, i.e. TNF-α blockers are 
expected to have a positive effect on reducing symptoms 
of various diseases associated with increased TNF-α 
activity (41-43). 
  Because of their demonstrated systemic benefit, there 
has been a recent interest in targeted intraocular 
treatment with anti-TNF-α drugs (41-43). So far, 2 anti-
TNF drugs have been used intravitreally and these are 
infliximab, a chimeric monoclonal antibody composed of 
human constant and murine variable regions, and 
adalimumab, a humanized monoclonal antibody. 
However, the available data on their intravitreal use is 
limited and does not appear to be promising. Infliximab, 
while shown to be effective in reducing macular oedema 
and vitritis, is associated with a significant risk of severe 
panuveitis and vitreous opacification (44).  This has led to 
a call for a moratorium on the clinical use of intravitreal 
infliximab outside well-monitored trials (45). Tsilimbaris 
and coworkers (46) investigated the safety of injecting 
adalimumab into the vitreous of in rabbits. Their data 
showed that intravitreal concentrations of up to 5 mg 
were not associated with any retinal toxicity. Clinical use 
of intravitreal adalimumab in uveitic CME also 
demonstrated no safety concerns; however, it failed to 




Methotrexate inhibits tetrahydrofolate synthesis by 
inhibiting the enzyme dihydrofolate reductase. Folic acid 
is important for the synthesis of DNA, RNA, and proteins. 
Methotrexate reduces B and T cell proliferation, and is 
commonly used either orally or subcutaneously at a 
dosage of 15–25 mg weekly in adult patients with uveitis 
(48).  
  Methotrexate is also effective for intraocular lymphoma 
when used intravitreally (49). This mode of delivery has 
more recently been tried in posterior segment uveitis 
however this was on a small scale (50). In a pilot study, it 
was found to be effective in reducing vitritis and macular 
oedema without raising IOP in patients with a history of 
steroid response. The onset of effect was within 1 week 
and lasted 4 months with no statistical difference found 
between the best visual acuity obtained after 
methotrexate injection and previous use of IVTA (51). 
 
CONCLUSION 
The goal of uveitis treatment is not only to suppress 
inflammation when it recurs but also to attain complete 
remission of inflammation, and thus prevent 
complications and permanent cumulative retinal damage 
(11). Therefore, long-term control of inflammation is 
crucial if vision to be preserved.  
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  Corticosteroids remain the mainstay of intraocular 
treatment of uveitis and uveitic CME, but their use has 
significant adverse effects in terms of cataract and raised 
IOP. Although Triamcinolone, the most commonly used 
intraocular steroid, is available at a low cost, Ozurdex® 
dexamethasone implant appears to have less adverse 
effects and lasts longer. Fluocinolone implants last up to 
two and a half years, which is an advantage in patients 
with chronic uveitis. However, their use is associated 
with a very high risk of cataract, and a significant 
percentage of patients require IOP reduction surgery. 
Retisert® is the one currently available for uveitis but its 
insertion requires surgery. As Iluvien® could be injected 
into the vitreous cavity through a minimally invasive 
procedure in an outpatient setting; it could in principle 
represent a more convenient treatment option for 
treating non-infectious uveitis in the future.  
  To circumvent the risks associated with corticosteroids 
use, several non-corticosteroid novel therapeutics have 
so far been explored such as intravitreal methotrexate, 
anti-VEGF, anti-TNF α and sirolimus with varying success. 
Methotrexate offers a better alternative to corticosteroid 
treatment than anti-VEGF agents; however, the 
published data supporting the use of intravitreal 
methotrexate in the treatment of uveitis is still limited 
and is based on small case series (51). Controlled trials 
would be required to confirm these outcomes. While the 
use of intravitreal anti-TNF α does not appear to be 
promising, sirolimus delivered as an intravitreal injection 
has previously demonstrated bioactivity as an 
immunomodulatory agent in reducing vitreous 
inflammation and could be a viable option pending the 
results of the phase III SAKURA study.  
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